Managing High-Risk Cutaneous SCC

View Activity

FACULTY

Chrys Schmults, MD, MSCE
Associate Professor of Dermatology
Harvard Medical School
Director, Mohs and Dermatologic Surgery Center
Brigham and Women’s/Dana Farber Cancer Center
Boston, USA

PROGRAM OVERVIEW

This case-based activity will cover the treatment and management of patients with cancer who are treated with or are eligible for treatment with recurrent or cutaneous squamous cell carcinoma.

TARGET AUDIENCE

This activity is designed to meet the educational needs of surgical dermatologists, dermatologists, head and neck surgical oncologists, medical oncologists, and other healthcare practitioners who care for patients with advanced or metastatic cSCC.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Review the immune escape mechanisms that contribute to the pathogenesis of cutaneous squamous cell carcinoma
  • Evaluate the new AJCC 8 cancer staging manual for head and neck cSCC and its application to clinical practice
  • Discuss the predictive features and risk factors for local recurrence or metastatic cSCC carcinoma and stratify patient risk for systemic disease
  • Describe the emerging immunotherapy clinical trial data in the treatment of advanced or metastatic cSCC

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity is planned and produced in accordance with ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent for their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with cutaneous squamous cell carcinoma cutaneous squamous cell carcinoma. CNE Credits: 1.0 ANCC Contact Hour(s).

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME)
Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Schmults discloses that she was on a Study site PI and/or steering committee member of: Regeneron, Castle Biosciences, Merck.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Melissa A Johnson, Sr. Program Manager of Med Learning Group has nothing to disclose.
Stephanie Wenick MPhil, Scientific and Medical Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certificate after completion of the activity.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: March 19, 2019

EXPIRATION DATE: March 19, 2020

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.